A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity

被引:264
作者
Rocchi, S
Picard, F
Vamecq, J
Gelman, L
Potier, N
Zeyer, D
Dubuquoy, L
Bac, P
Champy, MF
Plunket, KD
Leesnitzer, LM
Blanchard, SG
Desreumaux, P
Moras, D
Renaud, JP
Auwerx, J [1 ]
机构
[1] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France
[2] INSERM, CHRU, F-59037 Lille, France
[3] Glaxo Wellcome Inc, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA
[4] Glaxo Wellcome Inc, Dept Endocrinol, Res Triangle Pk, NC 27709 USA
基金
加拿大健康研究院; 澳大利亚研究理事会;
关键词
D O I
10.1016/S1097-2765(01)00353-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
FMOC-L-Leucine (F-L-Leu) is a chemically distinct PPAR gamma ligand. Two molecules of F-L-Leu bind to the ligand binding domain of a single PPAR gamma molecule, making its mode of receptor interaction distinct from that of other nuclear receptor ligands. F-L-Leu induces a particular allosteric configuration of PPAR gamma, resulting in differential cofactor recruitment and translating in distinct pharmacological properties. F-L-Leu activates PPAR gamma with a lower potency, but a similar maximal efficacy, than rosiglitazone. The particular PPAR gamma configuration induced by F-L-Leu leads to a modified pattern of target gene activation. F-L-Leu improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice, yet it has a lower adipogenic activity. These biological effects suggest that F-L-Leu is a selective PPAR gamma modulator that activates some (insulin sensitization), but not all (adipogenesis), PPAR gamma -signaling pathways.
引用
收藏
页码:737 / 747
页数:11
相关论文
共 45 条
[1]   The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].
Altshuler, D ;
Hirschhorn, JN ;
Klannemark, M ;
Lindgren, CM ;
Vohl, MC ;
Nemesh, J ;
Lane, CR ;
Schaffner, SF ;
Bolk, S ;
Brewer, C ;
Tuomi, T ;
Gaudet, D ;
Hudson, TJ ;
Daly, M ;
Groop, L ;
Lander, ES .
NATURE GENETICS, 2000, 26 (01) :76-80
[2]   Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice [J].
Berger, J ;
Bailey, P ;
Biswas, C ;
Cullinan, CA ;
Doebber, TW ;
Hayes, NS ;
Saperstein, R ;
Smith, RG ;
Leibowitz, MD .
ENDOCRINOLOGY, 1996, 137 (10) :4189-4195
[3]   PEROXISOME PROLIFERATOR AND RETINOID SIGNALING PATHWAYS COREGULATE PREADIPOCYTE PHENOTYPE AND SURVIVAL [J].
CHAWLA, A ;
LAZAR, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (05) :1786-1790
[4]   PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation [J].
Chawla, A ;
Barak, Y ;
Nagy, L ;
Liao, D ;
Tontonoz, P ;
Evans, RM .
NATURE MEDICINE, 2001, 7 (01) :48-52
[5]   N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.: 3.: Structure-activity relationship and optimization of the N-aryl substituent [J].
Cobb, JE ;
Blanchard, SG ;
Boswell, EG ;
Brown, KK ;
Charifson, PS ;
Cooper, JP ;
Collins, JL ;
Dezube, M ;
Henke, BR ;
Hull-Ryde, EA ;
Lake, DH ;
Lenhard, JM ;
Oliver, W ;
Oplinger, J ;
Pentti, M ;
Parks, DJ ;
Plunket, KD ;
Tong, WQ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) :5055-5069
[6]   N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.: 2.: Structure-activity relationship and optimization of the phenyl alkyl ether moiety [J].
Collins, JL ;
Blanchard, SG ;
Boswell, GE ;
Charifson, PS ;
Cobb, JE ;
Henke, BR ;
Hull-Ryde, EA ;
Kazmierski, WM ;
Lake, DH ;
Leesnitzer, LM ;
Lehmann, J ;
Lenhard, JM ;
Orband-Miller, LA ;
Gray-Nunez, Y ;
Parks, DJ ;
Plunkett, KD ;
Tong, WQ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) :5037-5054
[7]   A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity [J].
Deeb, SS ;
Fajas, L ;
Nemoto, M ;
Pihlajamäki, J ;
Mykkänen, L ;
Kuusisto, J ;
Laakso, M ;
Fujimoto, W ;
Auwerx, J .
NATURE GENETICS, 1998, 20 (03) :284-287
[8]   Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (BPARγ) heterodimer:: A basis for new therapeutic strategies [J].
Desreumaux, P ;
Dubuquoy, L ;
Nutten, S ;
Peuchmaur, M ;
Englaro, W ;
Schoonjans, K ;
Derijard, B ;
Desvergne, B ;
Wahli, W ;
Chambon, P ;
Leibowitz, MD ;
Colombel, JF ;
Auwerx, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (07) :827-838
[9]   Peroxisome proliferator-activated receptors: Nuclear control of metabolism [J].
Desvergne, B ;
Wahli, W .
ENDOCRINE REVIEWS, 1999, 20 (05) :649-688
[10]   L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ -: The role of Cys313 in ligand binding [J].
Elbrecht, A ;
Chen, YL ;
Adams, A ;
Berger, J ;
Griffin, P ;
Klatt, T ;
Zhang, B ;
Menke, J ;
Zhou, GC ;
Smith, RG ;
Moller, DE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) :7913-7922